Microart Inc. (MCRT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Microart Inc. (MCRT) trades at $0.00. Microart Inc. focuses on researching and developing stem cell solutions and therapeutic applications. Market cap: $26,149, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for MCRT: MCRT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MCRT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MCRT: 1/1 perspectives are bearish.
How is this calculated? →Microart Inc. (MCRT) Healthcare & Pipeline Overview
Microart Inc., founded in 1980 and based in Hong Kong, operates in the biotechnology sector, focusing on stem cell research and therapeutic applications. The company develops and commercializes cell-based anti-aging products and is also developing technology for diabetes treatment, positioning itself within the competitive healthcare landscape.
What Is the Investment Thesis for MCRT?
Microart Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its focus on stem cell research and therapeutic applications. The company's development of cell-based anti-aging products and diabetes treatment technologies could drive future revenue growth. However, the company's OTC listing and lack of financial data necessitate caution. Key catalysts include potential breakthroughs in its diabetes treatment technology and successful commercialization of its anti-aging products. Risks include the inherent uncertainty of biotechnology research, the competitive landscape, and the challenges associated with operating as an OTC-listed company with limited financial transparency. Investors should conduct thorough due diligence and assess their risk tolerance before considering an investment in Microart Inc.
Based on FMP financials and quantitative analysis
MCRT Key Highlights
- Microart Inc. was founded in 1980, indicating a long-standing presence in the biotechnology industry.
- The company focuses on stem cell research and therapeutic applications, a high-growth area within healthcare.
- Microart Inc. develops and commercializes cell-based anti-aging research and cosmetic products, providing a diversified revenue stream.
- The company is developing proprietary technology for the treatment of diabetes, addressing a significant global health challenge.
- Microart Inc. is based in Kowloon City, Hong Kong, positioning it within the Asian healthcare market.
Who Are MCRT's Competitors?
MCRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCRT's Key Strengths?
- Proprietary stem cell technologies.
- Focus on both therapeutic and cosmetic applications.
- Long-standing presence in the biotechnology industry (founded in 1980).
- Development of technology for diabetes treatment.
What Are MCRT's Weaknesses?
- OTC listing, indicating higher risk and lower liquidity.
- Limited financial information available.
- Small market capitalization ($0.00B).
- Dependence on research and development success.
What Could Drive MCRT Stock Higher?
- Potential breakthroughs in diabetes treatment technology.
- Successful commercialization of new anti-aging products.
- Strategic partnerships and collaborations with other companies.
- Expansion into new geographic markets.
- Positive results from stem cell research and development.
What Are the Key Risks for MCRT?
- Failure to obtain regulatory approvals for new products.
- Intense competition in the biotechnology industry.
- Economic downturns affecting consumer spending on cosmetic products.
- Limited financial disclosure and transparency due to OTC listing.
- Risk of research and development failures.
What Are the Growth Opportunities for MCRT?
- Expansion of Anti-Aging Product Line: Microart Inc. has the opportunity to expand its existing line of cell-based anti-aging research and cosmetic products. The global anti-aging market is projected to reach $421.4 billion by 2030. By introducing new and innovative products, Microart Inc. can capture a larger share of this growing market. The company can leverage its stem cell research to develop more effective and differentiated anti-aging solutions, potentially increasing revenue and market share.
- Commercialization of Diabetes Treatment Technology: Microart Inc.'s development of proprietary technology for the treatment of diabetes represents a significant growth opportunity. The global diabetes treatment market is projected to reach $135.7 billion by 2031. Successful development and commercialization of this technology could generate substantial revenue for the company. This would require clinical trials, regulatory approvals, and strategic partnerships to bring the product to market.
- Strategic Partnerships and Collaborations: Microart Inc. can pursue strategic partnerships and collaborations with other biotechnology companies, research institutions, and pharmaceutical firms. These partnerships can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its products. Collaborations can also help Microart Inc. expand its market reach and access new customer segments.
- Geographic Expansion into New Markets: Microart Inc. can expand its operations into new geographic markets, particularly in Asia and Europe. The increasing demand for anti-aging products and advanced therapies in these regions presents a significant growth opportunity. Entering new markets would require careful planning, market research, and adaptation of its products and marketing strategies to local preferences and regulations.
- Development of New Stem Cell-Based Therapies: Microart Inc. can invest in the development of new stem cell-based therapies for various diseases and conditions. The regenerative potential of stem cells offers promising avenues for treating a wide range of ailments. By focusing on innovative research and development, Microart Inc. can position itself as a leader in the stem cell therapy market and generate significant long-term growth.
What Opportunities Does MCRT Have?
- Expansion of anti-aging product line.
- Commercialization of diabetes treatment technology.
- Strategic partnerships and collaborations.
- Geographic expansion into new markets.
What Threats Does MCRT Face?
- Intense competition in the biotechnology industry.
- Regulatory hurdles and approval processes.
- Risk of research and development failures.
- Economic downturns affecting consumer spending on cosmetic products.
What Are MCRT's Competitive Advantages?
- Proprietary stem cell technologies.
- Established presence in the Hong Kong market.
- Focus on both therapeutic and cosmetic applications.
- Expertise in adult stem cell research.
What Does MCRT Do?
Microart Inc., established in 1980 and headquartered in Kowloon City, Hong Kong, is a biotechnology company focused on the research, development, and commercialization of stem cell solutions. The company's core business revolves around leveraging adult stem cells for therapeutic applications and developing innovative products in the anti-aging and cosmetic sectors. Microart Inc. is also actively involved in developing proprietary technologies aimed at treating diabetes, showcasing its commitment to addressing significant healthcare challenges. Microart Inc.'s product portfolio includes cell-based anti-aging research and cosmetic products, which are marketed to consumers seeking advanced skincare solutions. The company's research efforts are directed towards harnessing the regenerative potential of stem cells to develop effective therapies for various conditions. The company operates primarily in Hong Kong, with potential for expansion into other markets as its research and development efforts progress. Microart Inc. competes with other biotechnology companies in the stem cell research and therapeutic development space. Its focus on adult stem cells and its diversified product portfolio, spanning both therapeutic and cosmetic applications, differentiates it from some of its competitors. The company's long-standing presence in the industry, since 1980, provides it with valuable experience and insights into the evolving healthcare landscape.
What Products and Services Does MCRT Offer?
- Researches and develops stem cell solutions.
- Develops therapeutic applications of adult stem cells.
- Commercializes cell-based anti-aging research products.
- Commercializes cell-based cosmetic products.
- Develops proprietary technology for diabetes treatment.
- Focuses on leveraging adult stem cells for regenerative medicine.
How Does MCRT Make Money?
- Develops and patents stem cell technologies.
- Commercializes anti-aging and cosmetic products directly to consumers.
- Seeks partnerships for therapeutic applications of stem cells.
- Generates revenue through product sales and potential licensing agreements.
What Industry Does MCRT Operate In?
Microart Inc. operates in the biotechnology industry, a sector characterized by rapid innovation, high research and development costs, and significant regulatory oversight. The global biotechnology market is projected to reach $3.44 trillion by 2030, driven by advancements in genomics, proteomics, and stem cell research. Microart Inc.'s focus on stem cell solutions and therapeutic applications aligns with these trends. The company competes with other biotechnology firms, including CBDX, CLABF, ENDV, GMVDF, and HAVLF, that are also developing innovative therapies and products.
Who Are MCRT's Key Customers?
- Consumers seeking anti-aging and cosmetic products.
- Patients with diabetes (potential future market).
- Research institutions and pharmaceutical companies (potential partners).
- Healthcare providers (potential future market).
Company Profile
Microart Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kowloon City, HK. The company is led by CEO Tsap Wai Ping. MCRT has traded publicly since 2010.
MCRT Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
- Community sentiment has leaned positive, with discussions highlighting innovative product developments that could capture market share.
- Market perception has improved as analysts recognize the company's unique positioning in a niche sector, sparking interest among investors.
- Recent partnerships have been announced, enhancing Microart's credibility and opening new revenue streams, which could drive future growth.
Bear Case
- Concerns over market competition have surfaced, as similar companies are launching comparable products, potentially diluting Microart's market presence.
- Social sentiment has shown signs of skepticism regarding the company's ability to scale operations effectively in the current economic climate.
- Some community members express worries about the company's past performance, citing slow growth and missed targets as red flags for future expectations.
- Recent regulatory changes in the industry could pose challenges, creating uncertainty around compliance and operational costs for Microart.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MCRT Latest News
No recent news available for MCRT.
MCRT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCRT.
Price Targets
Wall Street price target analysis for MCRT.
MCRT MoonshotScore
What does this score mean?
The MoonshotScore rates MCRT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tsap Wai Ping
CEO
Information on Tsap Wai Ping's background is limited. As the CEO of Microart Inc., Tsap Wai Ping is responsible for leading the company's strategic direction, overseeing its research and development efforts, and managing its overall operations. Further details regarding Tsap Wai Ping's career history, education, and previous roles are not available.
Track Record: Due to limited information, it is not possible to assess Tsap Wai Ping's track record at Microart Inc. Key achievements, strategic decisions, and company milestones under their leadership are currently unknown. Further information is needed to evaluate their performance and contributions to the company's success.
MCRT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Microart Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Lack of regulatory oversight and investor protection.
- Going Concern Risk: The company's ability to continue as a going concern may be uncertain.
- Verify the company's legal status and registration.
- Assess the company's management team and their experience.
- Attempt to obtain and review any available financial statements.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Long-standing presence in the biotechnology industry (founded in 1980).
- Focus on stem cell research and therapeutic applications.
- Development of proprietary technology for diabetes treatment.
- Commercialization of cell-based anti-aging products.
MCRT Healthcare Stock FAQ
What does Microart Inc. do?
Microart Inc. is a biotechnology company focused on researching, developing, and commercializing stem cell solutions and therapeutic applications. The company develops and markets cell-based anti-aging research and cosmetic products, targeting consumers interested in advanced skincare. Additionally, Microart Inc. is actively developing proprietary technology for the treatment of diabetes, aiming to address a significant global health challenge. The company's business model centers around leveraging stem cell research to create innovative products and therapies for the healthcare and cosmetic markets.
What do analysts say about MCRT stock?
There is currently no available analyst coverage or consensus on Microart Inc. (MCRT) due to its OTC listing and limited financial disclosure. Key valuation metrics are not readily available, making it difficult to assess the company's financial performance and growth potential. Investors should conduct independent research and due diligence before considering an investment in MCRT, taking into account the inherent risks associated with OTC-listed companies and the biotechnology industry.
What are the main risks for MCRT?
The main risks for Microart Inc. include its OTC listing, which entails limited financial disclosure and transparency, potentially leading to higher price volatility and increased risk of fraud or manipulation. The company also faces intense competition in the biotechnology industry, as well as regulatory hurdles and approval processes for its products. Furthermore, the success of Microart Inc. depends on the outcome of its research and development efforts, which are inherently uncertain and subject to failure.
What are the key factors to evaluate for MCRT?
Evaluate MCRT on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does MCRT data refresh on this page?
MCRT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MCRT's recent stock price performance?
Microart Inc. (MCRT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary stem cell technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MCRT overvalued or undervalued right now?
Valuing Microart Inc. (MCRT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MCRT?
Before investing in Microart Inc. (MCRT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Microart Inc. due to its OTC listing and lack of financial disclosure.
- AI analysis pending for MCRT.